Company Focus
Chugai
Latest Chugai News
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Related News
Insights
Company Spotlight
A biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Latest News & Features of interest to Chugai
Biotechnology
Cambridge, UK-based clinical-stage biotech CellCentric has appointed Andy Fergus as chief development officer. 5 September 2024
Biotechnology
Acepodia has entered a strategic clinical collaboration with Pfizer Ignite to accelerate the development of its Antibody-Cell Conjugation (ACC) platform in autoimmune diseases. 4 September 2024
Biotechnology
Arsenal Biosciences, a programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, has announced the close of an oversubscribed $325 million Series C financing round. 4 September 2024
Pharmaceutical
Jazz Pharmaceuticals (Nasdaq: JAZZ) is to raise $850 million with the pricing of exchangeable senior notes, due 2030. 4 September 2024
Biotechnology
A new US biotech company—Adaptin Bio—has emerged from stealth with high hopes of overcoming one of medicine’s toughest hurdles. 4 September 2024
Pharmaceutical
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Biotechnology
Rigel Pharmaceutical’s shares dipped 4.4% to $12 .85 by late morning, despite announcing what could be a lucrative deal for the company. 3 September 2024
Biotechnology
The treatment landscape for paroxysmal nocturnal hemoglobinuria (PNH) continues to evolve with the introduction of new therapies. 3 September 2024
Biotechnology
Industry analysts forecast that North America is expected to lead the global cancer monoclonal antibodies market in the coming years, driven by an increasing incidence of cancer and favorable regulatory developments. 3 September 2024
Biosimilars
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
Latest In Brief for Chugai
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Latest Relevant Ones To Watch News
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
30 October 2024
28 October 2024
26 October 2024
23 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze